Ginkgo Bioworks Awarded $9.4 Million Subcontract to Develop Implantable Bioelectronic Devices

MT Newswires Live
2024-12-17

Ginkgo Bioworks (DNA) said Tuesday that it has been awarded a subcontract of up to $9.4 million to develop implantable devices for diagnosing and treating hormone disorders under the Advanced Research Projects Agency for Health's Resilient Extended Automatic Cell Therapies program.

The subcontract is in partnership with Carnegie Mellon University and will focus on bioelectronic cell-based technology, according to the company.

Price: 9.41, Change: -0.02, Percent Change: -0.21

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10